Skip to main content
Healthcare

STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

Feed excerpt — reported by STAT News

Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.